Lacosamide is NOT indicated for mood management
Lacosamide is approved exclusively for the treatment of partial-onset seizures in epilepsy, not for mood disorders. The FDA has not approved lacosamide for any psychiatric indication, including bipolar disorder, depression, or anxiety 1.
Regulatory Status and Approved Indications
Lacosamide is an antiepileptic medication that acts on voltage-gated sodium channels and is approved only for adjunctive treatment of partial-onset seizures in adults and children over 2 years of age 2. When regulatory agencies evaluated lacosamide for other indications (specifically painful diabetic neuropathy), both the FDA and European Medicines Agency rejected approval despite some positive trial data, citing concerns about inadequate efficacy evidence 2.
Evidence from Mood Disorder Guidelines
The most relevant guidelines for mood management explicitly exclude lacosamide from recommended treatments:
- Bipolar disorder guidelines (2007) list FDA-approved mood stabilizers including lithium, valproate, lamotrigine, and various antipsychotics, but make no mention of lacosamide 3
- These guidelines specifically note that gabapentin and topiramate were not found helpful in controlled studies for bipolar disorder 3—lacosamide is not even considered in this context
Neuropathic Pain Evidence (Not Mood)
The only non-epilepsy indication extensively studied for lacosamide was painful diabetic neuropathy, where it failed to gain approval:
- Multiple Phase 3 trials showed marginal or negative results 2
- A 2011 guideline concluded: "lacosamide is possibly not effective in treating PDN" and recommended it "should probably not be considered" (Level B recommendation) 4
Emerging Research on Mood Effects in Epilepsy Patients
While lacosamide is not indicated for mood management, recent research in epilepsy patients suggests potential secondary effects on mood:
- A 2018 prospective study found improvements in depression (BDI-II) and anxiety (STAI, HADS) scores that appeared independent of seizure control 5
- A 2020 systematic review concluded that while a negative effect on mood "seems unlikely," whether lacosamide has beneficial mood effects "remains controversial" with only Class III-IV evidence 6
- Recent studies (2025) in epilepsy patients with comorbid depression showed decreased depressive symptoms, possibly related to decreased IL-6 and increased serotonin levels 7, 8
Critical caveat: These mood improvements occurred in epilepsy patients receiving lacosamide for seizure control, not as primary mood treatment. The evidence level is insufficient to support using lacosamide for mood management 6, 9.
Clinical Bottom Line
Do not prescribe lacosamide for mood disorders. For bipolar disorder, use FDA-approved agents: lithium, valproate, lamotrigine, or atypical antipsychotics 3. For depression in epilepsy patients, standard antidepressants remain first-line. Any mood benefits observed with lacosamide in epilepsy patients are secondary findings requiring further validation and should not drive prescribing decisions for primary mood disorders.